Stroke Trials Network of Columbia and Cornell

哥伦比亚大学和康奈尔大学的中风试验网络(STNCC)的主要目标是 最大限度地扩大纽约的中风临床试验登记人数。哥伦比亚和康奈尔，位于 曼哈顿的西侧和东侧将分别形成两个枢纽，由一个急性 由布鲁克林和新泽西州的3家医院组成的治疗子网络，一个康复子网络 由韦斯特切斯特县和新泽西州的两个附属学术康复中心组成， 以及布鲁克林和纽约西部的4个学术医学中心。我们的枢纽和卫星 2016年治疗了略多于6700例中风。更重要的是，我们的RCC拥有广泛的领导层 在卒中临床试验中有记录，并有在卒中中处于领先地位的区别 StrokeNet前5年的临床试验；截至2017年8月，我们的总注册人数为375人 研究对象。从历史上看，在过去的10年里，哥伦比亚大学和康奈尔大学参与了44起 人类中风研究，包括29项中风临床试验，10项中风生物标记物研究，以及5项 中风结局研究。我们网络中的总体人口统计数据非常有利于 招收服务不足的少数族裔：哥伦比亚有40%的西班牙裔和25%的非洲人 美国人；康奈尔大学15%的亚洲人；圣约瑟夫大学24%的非洲裔美国人，30%的西班牙裔美国人，12% 其他的。我们的成功在一定程度上要归功于高度组织化和互动性的基础设施。我们持有 每月举行视频会议，由来自所有RCC中心和卫星的PI和协调员参加 网站，并标准化的日常中风入院筛查的整个RCC。这些数据也包括 因为在每月的视频会议上审查试行登记。STNCC还 在StrokeNet的头5年，在全国范围内发挥领导作用。联系皮伦道夫 马歇尔在NCC执行委员会任职的前3年，担任 五年教育培训核心，关于康复和康复工作 在过去的一年里。他已被邀请在即将到来的 续订期限。Co-I Ronald Lazar，现供职于UAB，曾在康复和康复工作组任职 三年了，Co-Pi E Sander Connolly一直在神经外科顾问小组服务。在……里面 在创新和临床试验开发方面，我们的RCC有提交 并为StrokeNet的两项新研究获得资金。STNCC联席是米切尔·埃尔金德和 胡曼·卡迈勒是阿卡迪亚试验的合作伙伴，这是一项多中心的3期随机对照试验，旨在确定 阿匹沙班治疗隐源性卒中合并“房颤”是否优于标准治疗 心脏病。“兰道夫·马歇尔、桑德·康诺利和罗纳德·拉扎尔是 CREST-H研究，CREST-2试验的辅助研究，测试假设 血管重建术可改善高度无症状AS患者的认知功能 颈动脉狭窄伴脑血流动力学衰竭。最后，我们的StrokeNet实习生计划 非常成功，5名学员在1年内完成了22篇摘要和21篇手稿 奖学金年，到目前为止有4个在主要学术机构担任助理教授的职位 机构(所有StrokeNet站点)。有两个人正在申请K奖。

The Stroke Trials Network of Columbia and Cornell (STNCC) has a primary goal of maximizing stroke clinical trial enrollment for New York. Columbia and Cornell, situated on the west and east side of Manhattan, respectively, will form the two hubs, supported by an Acute Treatment Sub-network of 3 hospitals in Brooklyn and New Jersey, a Recovery Sub-network comprising 2 affiliated academic Rehabilitation Centers in Westchester County and New Jersey, and 4 Academic Medical Centers in Brooklyn and in Western New York. Our hubs and satellites treated just over 6,700 strokes in 2016. More importantly, our RCC has an extensive leadership record in stroke clinical trials, and have the distinction of being the leading enroller in Stroke clinical trials over the first 5 years of StrokeNet; Our total enrollment as of August, 2017 was 375 subjects. Historically, over the last 10 years, Columbia and Cornell have been involved in 44 human stroke studies, including 29 stroke clinical trials, 10 stroke biomarker studies, and 5 stroke outcomes studies. The demographics in our network overall are very favorable for enrolling underserved minority populations: Columbia has 40% Hispanic and 25% African American; Cornell 15% Asian, and St. Joseph's 24% African American, 30% Hispanic, 12% other. Part of our success is due to the highly organized and interactive infrastructure. We hold monthly videoconferences attended by PIs and coordinators from all RCC hubs and satellite sites, and standardized daily stroke admission screening across the RCC. These data as well as trial enrollments are reviewed at the monthly videoconference calls. The STNCC has also provided leadership at the national level in the first 5 years of StrokeNet. Contact PI Randolph Marshall served on the NCC Executive Committee for the first 3 years, as Co-Chair of the Education and Training Core for all 5 years, and on the Recovery and Rehabilitation Working Group over the last year. He has been invited to continue the latter two roles in the upcoming renewal period. Co-I Ronald Lazar, now at UAB, served on the Recovery and Rehab WG for three years, and Co-PI E Sander Connolly has served on the Neurosurgery advisory group. In terms of innovation and clinical trial development, our RCC has the distinction of submitting and obtaining funding for two of the new StrokeNet studies. STNCC Co-Is Mitchell Elkind and Hooman Kamel are Co-PI's on the ARCADIA trial, a multi-center Phase 3 RCT to determine whether apixaban is superior to standard therapy for patients with cryptogenic stroke and “atrial cardiopathy.” Randolph Marshall, Sander Connolly, and Ronald Lazar are Co-PI's on the CREST-H study, an ancillary study to the CREST-2 trial, testing the hypothesis that revascularization can improve cognition in as subset of patients with high grade asymptomatic carotid stenosis who have cerebral hemodynamic failure. Finally, our StrokeNet trainee program has been highly successful, with 5 trainees producing 22 abstracts and 21 manuscripts within 1 year of Fellowship, and 4 so far have Assistant Professor positions at major academic institutions (all StrokeNet sites). Two are applying for K-awards.